Dr. Kotini Foundation is non-profit organization registered as trust,founded in 2013 at Rajampalem, West Godavari district of AndhraPradesh, India. It is founded by Dr. Suresh Babu Kotini.

Legal status and registrations:

  • Trust deed, Regd. No. 10/2013
  • Recognized & certified u/s 12AA of Indian Income tax Act 1961
  • Certified u/s 80G of Indian Income tax Act 1961
  • NGO DARPAN unique identification number: AP/2017/0162137
  • Dr. Kotini Foundation joined the Stop TB Partnership. Partnership Reference: 87507. Stop TB partnership administered by United Nations Office for Project Services (UNOPS). Stop TB Partnership. www.stoptb.org

Major objects:

  • Education
  • Promotion of science & research
  • Health care programmes etc.



Dear visitor,

Our foundation main focus is to provide quality education, promotion of science and research. We sponsor scholarships to the economically backward, wealthy talented young students for their quality higher education. We believe lack of education is one of the biggest barriers that prevent people from making a chance to healthy, quality and productive lives. Proper education plays a very crucial role in the contribution of making the better society which ultimately built the culture of peace.

In our vision, this will be achieved through providing quality education to the needy, deserved and economically disadvantaged students with immense God’s gifted talent. Due to the lack of financial support, those talents and intellectuals should never be wasted and should be properly utilized not only for the individual growth but also for the creation of better society. My policy is about providing scholarship is not only to make educated persons, but also to make them ‘knowledge persons’ those may participate in raising the GDP growth rate which allows the nation moving forward.

Another major focus of our mission is to work on science and research innovation projects in the area of drug (medicines) discovery in the medical filed for identification and development of novel antibiotics to treat life-threatening infectious diseases, in this case our scientific team focused on to identify and develop medicines (e.g. antibiotics) against mycobacterium tuberculosis, a causative agent of tuberculosis (TB) disease and ESKAPE pathogens (cause various infections).

It’s my belief that, I blessed with what I have now is through my quality higher education with immense exposure and access etc. To me, education is an admirable thing and is there anything which I could give back to society is that to provide quality education to economically disadvantaged meritorious students who are with good discipline and putting all possible efforts in research for the development of new/novel class of medicines against life-threatening infectious diseases. This is my sole motivation to establish this foundation (non-profit organization) to fill the gap in the knowledge. To this end, working on this big goal with constructive and innovative strategies, we hope and look forward to get the chance for the better life and bright future.

Yours faithfully,
Dr. Suresh Babu Kotini, PhD
Founder & President


  • Education- Inspire scholarship programme:

    This programme is designed for the financial support to economically backward, exceptionally talented and disciplined students for their education. Application of Inspire scholarship programme can be downloaded at downloads tab.

  • Science and Research innovation programmes:
    This programme is mainly designed for the identification and development of various antibiotics to treat life-threatening infectious diseases.

  • Identification and development of novel/new class of antibiotics against multi-drug resistant Mycobacterium tuberculosis

Mycobacterium tuberculosis (Mtb) is a major human pathogenic bacteria and the causative agent of Tuberculosis (TB) disease. In the most cases, TB is treatable and curable. However, people with TB can die if they do not get proper treatment. Sometimes drug-resistant TB occurs when bacteria becomes resistant to the drugs used to treat TB. This means that the drug can no longer kill the bacteria. TB is highly infectious disease, declared a global health emergency by the World Health Organization (WHO) and is still the second leading killer in the world. According to WHO, in 2017, approx. 11 million (1.1 core) people infected/fell ill with TB disease, and approx. 2 million (20 lakhs) people died from TB disease worldwide and India is the leading the count. This means that, approx. 5,000-6,000 people die each day due to TB disease. Unfortunately, the lack of adherence to prescribed treatment procedure and inefficient healthcare structure have contributed to the development of multidrug-resistant TB (MDR-TB), defined as resistance to at least isoniazid and rifampicin, two front-line drugs used for treatment of TB that requires at least 20 months of treatment of second-line drugs comprised of capreomycin, kanamycin, amikacin and fluoroquinolones; these are more toxic and less efficient, which cure rates in the range of 60-70%. In patients affected by extensively drug-resistant (XDR)-TB, the chances of successful treatment are quite low, underpinning the need for urgent discovery of novel compounds with activity against Mtb strains resistant to second-line drugs and search for new antitubercular drugs is a priority so as to overcome the problem of drug resistance and to finally eradicate TB disease.

  • Identification and development of novel/new class of antibiotics against ESKAPE pathogens

The need of new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens are the leading cause of nosocomial infections (hospital-acquired infections- HAIs) throughout the world. ESKAPE pathogen causes various life-threatening serious infections e.g., Enterococcus faecium causes urinary tract infections, bacteremia, endocarditis, intra-abdominal & pelvic infections, Staphylococcus aureus causes skin infections, pneumonia, meningitis, osteomyelitis, endocarditis, toxic shock syndrome, bacteremia, spesis and wound infections, Klebsiella pneumonia causes pneumonia, blood stream infections, wound infections, urinary tract infections and meningitis, Acinetobacter baumannii causes bacteremia, pneumonia, meningitis, urinary tract infections, wound infections, Pseudomonas aeruginosa causes pneumonia, urinary tract infections, bacteremia, Enterobacter species (Enterobacter cloacae, Enterobacter areogenes etc.) causes respiratory tract infections and urinary tract infections etc. Most of them are multidrug isolates, which is one of the greatest challenges in clinical practice. Multidrug-resistant is amongst the top three threats to global public health and is usually caused by excessive drug usage or prescription, inappropriate use of antimicrobials and substandard pharmaceuticals. Understanding the resistance mechanisms of these bacteria and the development of novel antimicrobial agents (antibiotics) is urgent.



Professional experience/Research/Education:

  • Board of Director (since 2016) at Suzen Medicare Private Limited, Hyderabad, India
  • President & Scientific Director (since 2015) at Dr. Kotini Foundation, India
  • Associate Investigator (Senior Scientist) (2014-2015) at Dept. of Physical Biochemistry, Max Planck Institute for Biophysical Chemistry (Max Planck Society), Gottingen, Germany
  • Post-doctoral scientist (2011-2014) at Dept. of Physical Biochemistry, Max Planck Institute for Biophysical Chemistry (Max Planck Society), Gottingen, Germany
  • Ph.D. in Biochemistry & Molecular Biology (2007-2011) at Dept. of Physical Biochemistry, Max Planck Institute for Biophysical Chemistry (Max Planck Society), Gottingen, Germany. Ph.D. thesis advisor: Prof. Dr. Marina V Rodnina (Directors of the Max Planck Society),
  • Research Fellow (2004-2007) at CSIR-Centre for Cellular and Molecular Biology (CCMB), Hyderabad, India
  • MSc. in Microbiology (2002-2004) from Acharya Nagarjuna University, Guntur, India



Honors/awards/research grants received:

  • In 2007, Selected for International PhD programme of GGNB (Gottingen Graduate School for Neurosciences, Biophysics, and Molecular Biosciences) to pursue Ph.D. at Max Planck Institute for Biophysical Chemistry, Gottingen, Germany
  • Max Planck Society stipend for doctoral research (2007-2011)
  • Dr.rer. nat. (Doctor of Natural Science) awarded (2011) with “Magna Cum Laude” (“with great honor) by the University of Gottingen, Gottingen, Germany
  • Research grants received (2011-2015) from German Research Foundation(DFG) & Max Planck Society to carry out research at Max Planck Institute for Biophysical Chemistry, Gottingen, Germany




  • Print Media (National and International Newspapers)- Antibiotic resistance and human health threat levels:
  • Approval of Income-Tax Exemption U/S 80G(5)(V) & 80G(5)(vi) of Income Tax Act, 1961.
    Issued by commissoner of Income Tax:



Registered Office

Corporate Office